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Acute and Remote Thrombotic Complications in Patients with
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From 1Military Medical Academy, Belgrade; 2Institute of Cardiovascular Disease "Belgrade", Belgrade; 3Clinical
Hospital Center "Zemun", Belgrade; 4Clinical Hospital Center "Kragujevac", Kragujevac, Serbia
STOJANOVI ET AL: Acute and Remote Thrombotic Complications in Patients with Implanted Drug-eluting
Stents; Influence of Smoking as a Risk Factor. The use of percutaneous coronary intervention (PCI) with the
procedural success and continuous technological improvements contributed to a better treatment of coronary heart
disease also resulted in the development of acute and remote thrombotic complications. Environmental factors such
as smoking significantly worsen unwanted cardiac events after percutaneous coronary intervention. The aim of this
study was to determine the influence of risk factors (smoking) the number and severity of adverse cardiac events and
its possible selective effect on the formation of acute and subacute thrombotic complications during the application of
stents coated with paclitaxel (PES) and sirolimus-coated stents (SES). The study was based on a five-year follow-up
of all consecutive patients at the Institute for Cardiovascular Diseases Dedinje in which are embedded drug-eluting
stents with sirolimus (Cyphar) and paclitaxel (Taxus). Average age of the tested population was 68.4±8.4 years, of
which 585 patients were men (83.4%) and 116 (16.6%) women. Four patients (0.6%) died. Myocardial infarction
occurred in nine patients (1.3%). The overall incidence of MACE events was 14.5%, which was registered in 102
patients. Stent thrombosis, definite criteria according to ARC, occurred in 22 patients (3.14%). Probable stent
thrombosis was observed in 1 patient (0.14%), possible stent thrombosis in 1 patient (0.14%). Sirolimus and paclitaxelcoated stents are safe and effective means of percutaneous coronary interventions conducted for treatment of
atherosclerotic coronary artery disease. Research has shown a large impact of smoking as a risk factor in the development
of adverse cardiac events. (J HK Coll Cardiol 2019;27:1-10)
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Introduction
The use of percutaneous coronary intervention
(PCI) for the treatment of coronary ischemic disease
experienced a dramatic expansion in the past two
decades. At the same time, procedural success, safety
and durability PCI dramatically improved due to
continuous technological improvements, the
periprocedure prepare patients and better understanding
early and late complications of treatment. These
improvements support the expansive use of PCI as
definitive therapy.1,2
Application of stents still has the effect of two
potentially very significant complications, such as stent
thrombosis and restenosis at the site of installation.
Therefore, attempts to create stents that will be less
thrombogenic and that will cause less inflammatory
reaction, and reduce the aforementioned complications
to a minimum. Stents coated with biocompatible
materials are not significantly reduce major adverse
cardiac events. Unlike biocompatible stents, stents with
sirolimus and paclitaxel have proved to be very effective
in reducing unwanted cardiac events.3,4
Smoking is one of the major risks of coronary
artery disease. It is known that the risk of coronary heart
disease is twice as high in smokers. It is believed that
nicotine increases the mortality rate in patients with
coronary artery disease by about 30%. The attacks of
angina are more common in smokers in about 3 times,
and last about 12 times longer. This is due to the increase
in pulse rate and blood flow resistance which burdens
the heart muscle. In a country where 40% of the
population smokes and how this needs to warn of this
danger. One should know that smoking is a sign
unenlightenement and delays in the acceptance of
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scientific knowledge. Despite the huge loss of human
lives smoking significantly affects the expenditure
envisaged for health.5,6
In relation to the timing of the stent thrombosis it
is divided into:
• Acute − 24 hours after stent implantation,
• Subacute − 24 hours to 30 days after stent implantation,
• Late − 30 days to 1 year after stent implantation,
• Very late − more than one year after stent implantation.
The definition of stent thrombosis was proposed by
the Academic Research Consortium (ARC). Some
authors believe that the use of precisely ARC definitions
of stent thrombosis provides the best estimate of the
true prevalence of this phenomenon.
According to this classification stent thrombosis are
divided into:
• Definitive − angiographic evidence of stent thrombosis
with clinical signs of myocardial ischemia within 48
hours (chest pain with ECG changes or an increase of
cardiac enzymes). Pathological evidence of stent
thrombosis,
• Probable − unexplained death within 30 days after
stent implantation. Myocardial infarction region
stentirane artery
• Possible − the unexplained death after more than 30
days after stent implantation.7

Aim
Based on all the above aim of this study was to
determine the influence of risk factors (smoking) the
number and severity of adverse cardiac events and their
possible selective effect on the occurrence of acute and
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subacute thrombotic complications during the
application of stents coated with paclitaxel (PES) and
sirolimus-coated stents (SES) .

Hypothesis
Based on the literature data is not expected
difference in the security application of stents coated
with paclitaxel and sirolimus-coated stents with regard
to the occurrence of acute and remote thrombotic
complications.

Materials and Methods
Five-year follow-up of all consecutive patients
at the Institute for Cardiovascular Diseases Dedinje, in
which the embedded drug eluting stents with
sirulimusom (Cypher) and paclitaxel (Taxus).
Monitoring methods: ambulatory visits, and
telephone contact with the patient. The study was
retrospective, clinical, nonintervention, with the followup period of five years for an individual patient. Data
on the patients included in the database formed to
monitor. Enter their demographic, clinical, angiographic
data.
Telephone interview with patients was based on
a questionnaire containing the contact details of the
patient, date of the telephone contact, presence of
diabetes mellitus, evaluation angina eventual death of
the patient, information on the occurrence of death,
hospitalization for cardiac reasons, myocardial
infarction, percutaneous coronary reintervention or
surgical myocardial revascularization. The questionnaire
contains questions related to all the drugs taken by the
patient after the intervention, especially acetyl-salicylic
acid, ticlopidine or clopidogrel, thienopyridine
derivatives duration of therapy, statin therapy, the
presence of risk factors (hiperlipoproteinemia, smoking).
Based on the questionnaire, if judged to have significant
angina patients, the patients were invited to a preview
on an outpatient basis of which were sent to the existence
of non-invasive testing provoked ischemia, and in case
of ischemia, were sent to coronary angiography and
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subsequent percutaneous myocardial revascularization
or surgery or resume conservatively therapy.
Significant adverse cardiac events, MACE are
defined as follows. Death is defined as cardiac or
noncardiac origin. The death of unknown cause was
recorded as cardiac origin. On the basis of ischemic
changes in the ECG and / or an increase in CK three
times the upper limit of the laboratory reference value,
an increase in troponin T above the upper limit of
reference values were used for the definition of
myocardial infarction.
All reintervention within the stent implanted
during the index procedure, as well as 5 mm proximal
or distal edges of the stent imlantiranog classified as retarget lesion revascularization, TLR (target lesion
revascularization). Other percutaneous coronary
intervention on the same blood vessel outside the defined
zones are defined as repeat revascularization of the target
vessel, TVR (target vessel revacularization).
Accompanied by the outcome of patients in the
study group was also stent thrombosis according to ARC
criteria.
Initially the study included 800 patients who
underwent percutaneous coronary angioplasty. After the
indexing procedure clinical monitoring is completed
for 701 (87.6%) patients whose data after the
completion of the follow-up period subjected to
statistical analysis. Ninety-nine patients (12.3%) were
not available for cooperation. Of the 701 patients in
whom were implanted stents, 340 patients were
implanted stents coated with sirolimus and in 361
patients with paclitaxel-coated.

Statistical Analysis
In case of continuous data, variables were
presented as mean value ± standard deviation (SD).
Some of the variables were presented as frequency
of certain categories, while statistical significance of
differences was tested with the Chi square test. In the
case of low frequencies, probability is calculated by
Fisher's Exact test.
The Kaplan-Meier non-parametric statistic was
used to estimate the survival function of clinical outcome
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(MACE events) in nonsmokers and smokers. Post hoc
analysis was done by using log rank test.
Differences between groups were considered
significant at p<0.05. Complete statistical analysis of
the data was conducted with the statistical software
package, SPSS Statistics 18 (Chicago, Illinois, USA).

Results
Average age of the tested population was 68.4 +/8.4 years, of which 585 patients were men (83.4%).
Four patients (0.6%) died. Two patients death is
of noncardiac origin, so that the two patients had fatal
consequence of cardiac events. The occurrence of angina
prompting the 288 patients (36.8%). Load test was
positive in 215 patients (30.7%). Myocardial infarction
occurred in nine patients (1.3%). Re-PCI was performed
in 103 patients (14.7%). Surgical revascularization was
performed in 42 patients (5.8%). The overall incidence
of MACE events was 14.5%, or 102 pancijenata.
Repeated coronary angiography was performed in 230
patients (32.8%).
Stent thrombosis, definite criteria according to
ARC, occurred in 22 patients (3.14%), 5 patients
(0.7%) were treated with CABG, and in 17 patients
(2.4%) is done re-pci. Probable stent thrombosis in
1 patient (0.14%), possible stent thrombosis in 1 patient
(0.14%).
Of the 24 patients in whom stent thrombosis
occurred 10 (1.4%) had a stent coated with sirolimus,
14 (2%) had a stent coated with paclitaxel.
Of the 22 patients who came forward certain stent
thrombosis, 12 (1.7%) patients had a stent coated with
paclitaxel, 10 (1.4%) patients had a stent coated with
sirolimus. Probable stent thrombosis occurred in 1
(0.14%) patients with paclitaxel, possible stent
thrombosis occurred in 1 (0.14%) patients with
paclitaxel.
Distribution of patients according to the type of
stent implanted (Table 1).
After implantation of the two types of stents when
it comes to survival, there was no statistically significant
difference, despite the fact that all patients with lethal

4

results belonged to the group of PES (Table 2).
When it comes to myocardial infarction showed
statistically significantly greater number of myocardial
infarction in the PES group (p=0.004) (Table 3).
When it comes to TLR all registered cases
(N=31), took place on implanted PES (p<0.001)
compared to the group SES (Table 4).
When it comes to TVR more than ¾ of registered
cases (N=56) occurred in patients belonging to the group
SES (p<0.001), statistically highly significant difference
(Table 5).
Speaking of MACE no significant difference
between the two types of stents (Table 6).
Distribution of patients (habit of smoking) in
relation to the type of implanted stent is uniform between
groups SES and PES (Table 7).
Table 1. Distribution of patients using 2 different
drug eluting stents
Percutaneouscoronary
intervention
SES
PES
Total

Number

%

340
361
701

48.5
51.5
100.0

Table 2. Clinical outcome and stent types
implantation
Stents
Outcome

SES

PES

Total

Survivors

N
(outcome)
(stents)

340
48.8%
100.0%

357
51.2%
98.9%

697
100.0%
99.4%

Died

N
(outcome)
(stents)

0
0.0%
0.0%

4
100.0%
1.1%

4
100.0%
0.6%

Total

N
(outcome)
(stents)

340
48.5%
100.0%

361
51.5%
100.0%

701
100.0%
100.0%

Statistics
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months). Using a log-rank test showed a statistically
significant difference between these two groups
(p=0.013) (Table 11).

A statistically significantly higher number of
smokers completed annually in the PES group (p=0.048)
(Table 8).
Statistically significantly higher MI in the PES
group of smokers (Table 9).
Statistically significantly higher number of
MACE in the PES group of smokers (Table 10)
Based on statistical processing (Table 10) and
Kaplan-Mayer curve (Figure 1), it is concluded that in
non-smokers, 50% of MACE occurs after 61,714
months, and smokers are slightly earlier (60,180

Stent thrombosis (TS) is a rare but potentially
fatal complication of percutaneous coronary intervention
(PCI). The frequency of TS varies in literature depending
on the type of stent, it presents patients with stable angina

Table 3. Myocardial infarction and stent types
implantation

Table 5. Target vessel revascularization (TVR) and
stent types implantation

Myocardial

Discussion

Stents

infarction

Stents

SES

PES

Total

TVR

SES

PES

Total

No

N
(outcome)
(stents)

340
49.1%
100.0%

352
50.9%
97.5%

692
100.0%
98.7%

Survivors

N
(outcome)
(stents)

284
45.1%
83.5%

346
54.9%
95.8%

630
100.0%
89.9%

Yes

N
(outcome)
(stents)

0
0.0%
0.0%

9
100.0%
2.5%

9
100.0%
1.3%

Yes

N
(outcome)
(stents)

56
78.9%
16.5%

15
21.1%
4.2%

71
100.0%
10.1%

Total

N
(outcome)
(stents)

340
48.5%
100.0%

361
51.5%
100.0%

701
100.0%
100.0%

Total

N
(outcome)
(stents)

340
48.5%
100.0%

361
51.5%
100.0%

701
100.0%
100.0%

Statistics

Chi-Square = 8.587; p=0.004

Table 4. Target lesion revascularization (TLR) and
stent types implantation

Statistics

Chi-Square = 27.837; p=0.000

Table 6. Major adverse cardiac event (MACE) and
stent types implantation

Stents
TLR

Stents

SES

PES

Total

MACE

SES

PES

Total

No

N
(outcome)
(stents)

340
50.7%
100.0%

330
49.3%
91.4%

670
100.0%
95.6%

No

N
(outcome)
(stents)

284
47.4%
83.5%

315
52.6%
87.3%

599
100.0%
85.4%

Yes

N
(outcome)
(stents)

0
0.0%
0.0%

31
100.0%
8.6%

31
100.0%
4.4%

Yes

N
(outcome)
(stents)

56
54.9%
16.5%

46
45.1%
12.7%

102
100.0%
14.6%

Total

N
(outcome)
(stents)

340
48.5%
100.0%

361
51.5%
100.0%

701
100.0%
100.0%

Total

N
(outcome)
(stents)

340
48.5%
100.0%

361
51.5%
100.0%

701
100.0%
100.0%

Statistics

Chi-Square = 28.550; p=0.000
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pectoris and acute coronary syndrome in the study, etc.
The obtained data on the incidence of stent thrombosis
are consistent with the data obtained in many world
studies.
The success of drug-coated stents is highly
dependent on each component of the complex as well
as the interactions among the elements of the complex.
Different DES have different potential to inhibit
neointimal proliferation. 8,9 Given the fact that the
experiments on animal models can not be directly

translated to human populations, using the results of
clinical studies.
In cardiology, as in any other branch of medicine
revived the concept of 'evidence-based medicine'. On a
number of important questions attempted to come up
with an answer through a well-designed, controlled,
prospective, randomized trials.10,11
The first positive clinical data on the
implementation of DES come from a study that
examined the use of rapamycin (Sirolimus trade name)

Table 7. Distribution of smokers regarding stent
types implantation

Table 9. Myocardial infarction in smoking patients
regarding stent types implantation

Stents
Smokers

Miocardial

SES

PES

Total

Stents

infarction

SES

PES

Total

No

N
(outcome)
(stents)

210
46.2%
61.8%

245
53.8%
67.9%

455
100.0%
64.9%

No

N
(outcome)
(stents)

130
54.9%
100.0%

107
45.1%
92.2%

237
100.0%
96.3%

Yes

N
(outcome)
(stents)

130
52.8%
38.2%

116
47.2%
32.1%

246
100.0%
35.1%

Yes

N
(outcome)
(stents)

0
0.0%
0.0%

9
100.0%
7.8%

9
100.0%
3.7%

Total

N
(outcome)
(stents)

340
48,5%
100.0%

361
51.5%
100.0%

701
100.0%
100.0%

Total

N
(outcome)
(stents)

130
52,8%
100,0%

116
47.2%
100.0%

246
100.0%
100.0%

Statistics

Chi-Square = 2.60; p=0.107

Table 8. Lethal outcome in smoking patients
regarding stent types implantation

Statistics

Fisher's Exact Test = 8.38; p=0.001

Table 10. Major adverse cardiac event (MACE) in
smoking patients regarding stent types implantation
Stents

Stents
Outcome

SES

PES

Total

MACE

SES

PES

Total

Survivors

N
(outcome)
(stents)

130
53.7%
100.0%

112
46.3%
96.6%

242
100.0%
98.4%

No

N
(outcome)
(stents)

113
56.8%
86.9%

86
43.2%
74.1%

199
100.0%
80.9%

Died

N
(outcome)
(stents)

0
0.0%
0.0%

4
100.0%
3.4%

4
100.0%
1.6%

Yes

N
(outcome)
(stents)

17
36,2%
13,1%

30
63.8%
25.9%

47
100.0%
19.1%

Total

N
(outcome)
(stents)

130
52.8%
100.0%

116
47.2%
100.0%

246
100.0%
100.0%

Total

N
(outcome)
(stents)

130
52,8%
100,0%

116
47.2%
100.0%

246
100.0%
100.0%

Statistics

6
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coated stents (SES). Rapamycin is a natural macrocyclic
lactone with potent antiproliferative, anti-inflammatory
and immunosuppressive action of the inhibitory effect
on the activation of the target sites for rapamycin mammalian target of rapamycin (mTOR), ultimately
leading to cell cycle arrest.12,13
Cypher (Cordis, Johnson & Johnson) is a stainless
steel stent covered with a very thin layer of polymer
containing neerodirajuæeg rapamycin. The first
implantation of Cypher stent is made in the First in Man
(FIM) clinical study in Sao Paulo, Brazil and Rotterdam,
the Netherlands. Four months after implantation, by
using intravascular ultrasound and quantitative coronary
angiography, in both studies was demonstrated minimal
neointimal hyperplasia. In the Brazilian study of
intravascular ultrasound after 4 years of follow-up
showed continued suppression of intimal hyperplasia
in a group of 30 patients with slow-releasing SES, with
survival without significant clinical events by 87%.14
This test has demonstrated a low incidence of
stent thrombosis (definite, probable, possible) and
thereby simultaneously demonstrated safe use of stents
coated with the drug.
The results of our study were compared with
published results of the studies and meta-analyzes that
examined the long-term safety and efficacy of drugcoated stents, either through long-term monitoring of
patients revascularized only the implantation of DES,

or in comparison to patients who were implanted with a
metal stent is not coated with a drug.15,16 We analyzed
primarily studies published in reputable journals and
reference cardiology.
Demographic, clinical and angiographic
characteristics of the study group in our study are in
accordance with the same characteristics examined
groups in the studies in which they are declared.
The research showed that the use of drug-eluting
stents to treat coronary disease showed a low incidence
of major cardiac events (death, MI, TLR, TVR) during
the follow-up of five years. Application of DES leads to
lower rates of repeat revascularization (percutaneous
coronary intervention or bypass surgery).
Analyses have shown the safety of the use of
drug-coated stents, and in particular to the emergence
of thrombosis which is not higher in DES compared to
the BMS.17,18 The occurrence of thrombosis in BMS was
studied in many international studies and the data
obtained are in favor of the data from our study where
they analyzed patients with drug-coated stents, to the
emergence of thrombosis in DES is not greater than the
occurrence of thrombosis in BMS. Meta-analyzes may
increase the strength of the evidence of individual
studies, but also to distinguish quality (indicate) the
effects of certain methods of treatment. A meta-analysis

Table 11. Cumulative probability of MACE events
in nonsmokers and smokers (Kaplan-Maier method;
N=701)
Mean*
95% Confidence
Interval
Smokers Estimate

Std.
Error

Lower
Bound

Upper
Bound

No

61.714

0.454

60.824

62.605

Yes

60.191

0.763

58.696

61.686

Total

61.180

0.399

60.397

61.962

*Median could not be obtained due to distribution of MACE
data

J HK Coll Cardiol, Vol 27

Figure 1. Cumulative probability of MACE events in
nonsmokers and smokers (five-year follow-up).
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of randomized studies on the implementation of
medication-coated stents compared to uncoated (Fushs
AT et al., 2008) included 28 randomized studies that
have been analyzed stent thrombosis patients undergoing
DES, BMS and balloon angioplasty. The total number
of patients from the DES group was from 5612 a BMS
Group 7639th Stent thrombosis occurred in 107 patients
(1.05%), of which 56 patients were from the DES groups
(1.01%) and 51 patients were from BMS groups
(1.10%). The results showed no significant differences
between the two groups (OR = 0.87, 95% CI 0.58 to
1.3, p<0.48). Subacute thrombosis occurred in a total
of 21 patients, of which 0.43% of the DES group and
0.53% in BMS groups (OR = 0.86, 95% CI 0.50 to 1.5,
p<0.6) . Late stent thrombosis occurred in 27 patients
(1%) in the DES group and 20 patients (0.8%) in the
BMS groups (OR = 0.92, 95% CI 0.50 to 1.68, p<0.78).
After 12 months of intervention results showed a similar
incidence of subacute thrombosis and late thrombosis
in all types of PCI.19
The study, Goy, and associates from 2009
analyzed 350 patients with a SES embedded between
April and December 2002 in three Swiss hospitals.
Patients were 63 +/- 6 years, 78% were men, 20% had
acute coronary syndrome, 19% were patients with
diabetes. Stent thrombosis occurred in 12 patients
(3.6%). Definitive stent thrombosis occurred in 6
(1.8%), probable 1 (0.3%), possible 5 (1.5%). Eightyone patients were without complications. MACE events
occurred in 74 patients (21%): cardiac death 10 (3%),
unborn death 16 (5%), myocardial infarction 6 (2%),
TLR 26 (8%), TVR 9 (3%), by-pass graft 6 (2%).20
In our research, after implantation of the two types
of stents, when it comes to survival, there was no
statistically significant difference, despite the fact that
all patients with lethal results belonged to the group of
PES. Join a statistically significantly greater number of
myocardial infarction in the PES group (p=0.004). When
it comes to TLR all registered cases (N=31), took place
on implanted PES (p<0.001). In more than ¾ of
registered cases (N=56) TVR occurred in patients
belonging to SES group (p<0.001). There is no
significant difference between the two types of stents
in terms of MACE

8

Smoking is the most important modifiable risk
factor for coronary disease and the leading cause of death
in developed countries. Today in the world smokes about
one billion people. The risk of myocardial infarction is
high even among smokers if they are exposed to passive
smoking. Among those who smoke 20 or more cigarettes
daily have a triple increase in total coronary heart
disease. Our research showed significant statistical
association of smoking as a risk factor and the occurrence
of fatal outcome, despite the fact that the number of
deaths was not alarming. Smoking as a risk factor
significantly contributes to the occurrence of myocardial
infarction (highly statistically significantly contributes
to the occurrence of myocardial infarction). Smoking
also significantly affects the occurrence of MACE.
Prospective multicentre German Drug-Eluting
Stent Registry (DES.DE) analyzed and identified 1,122
patients who had never smoked and 1,052 patients who
were current smokers. Smokers were younger (56.5 vs.
69.4 years, p<0.0001), more often males, with less
frequent diabetes and hypertension compared to nonsmokers. Smokers presented more often with acute
coronary syndromes. After a mean follow-up of
12.5 months, smokers had both higher mortality (4.6
vs. 2.7%, p<0.05) and myocardial infarction (MI) rates
(4.9 vs. 3%, p<0.01). There was no significant difference
between smokers and non-smokers in the rate of target
vessel revascularization (9.8 vs. 11.4%, p=0.26). Major
adverse cardiac and cerebrovascular events (defined as
the composite of death, MI and stroke, MACE) were
higher in smokers (10.6 vs. 6.1%, p<0.001). Moreover,
after adjustment for baseline clinical and angiographic
variables, smoking continued to be a strong independent
predictor for MACE (OR = 2.34, 95% CI 1.49-3.68).
In a subgroup analysis, we found that the increased risk
of smoking was most prominent in patients presenting
with stable angina pectoris (OR = 3.71, 95% CI 1.24-2.57,
p<0.05). Smoking almost doubled the risk for MACE
in acute MI patients, though this did not reach statistical
significance (adjusted OR = 1.91, 95% CI 0.93-3.94,
p=0.74).
This large multicentre DES registry provides
evidence that smokers treated with DES, despite lower
i n c i d e n c e o f p r e d i s p o s i n g r i s k f ac t o r s fo r
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atherosclerosis, experience higher rates of death and MI
compared to non-smokers, particularly in the setting of
stable coronary artery disease. Smoking has only
marginal effects on target vessel revascularization rates
in patients treated with DES.21

Conclusion
Sirolimus and paclitaxel-coated stents are safe and
effective means of percutaneous coronary interventions
used for treatment of atherosclerotic coronary artery
disease.
Our results agree with the results of randomized
clinical trials and large registries which examined
sirolimus and paclitaxel-coated stents.
Our research showed that the use of drug-eluting
stents to treat coronary disease has a low incidence of
major cardiac events (death, MI, TLR, TVR) during the
period of five years examined groups of patients.
Application of DES leads to lower rates of repeat
revascularization (percutaneous coronary intervention
or bypass surgery).
The significance of our study is the presentation
of results from clinical practice follow-up of patients
due to the current problem of stent thrombosis with the
drug-coated stents. The results of low incidence of stent
thrombosis are in favor of safe use of stents coated drug.
Research has shown a large impact of smoking as
a risk factor in the development of adverse cardiac
events. There is a significant correlation between
smoking as a risk factor and the occurrence of a lethal
outcome, and if the number of deaths was not alarming.
Smoking as a risk factor also significantly contributes
to the occurrence of myocardial infarction (highly
statistically significantly contributes to the occurrence
of myocardial infarction).
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